Best Microbiome Supplements: How to Evaluate Any Label

Why this guide is not a ranking

Almost every article about the best microbiome supplements is a list of brands in an order someone decided on. That format has a structural problem: efficacy in this field is strain-specific and outcome-specific, so a ranking of products is a ranking of the wrong unit. A systematic review of 228 randomised controlled trials covering 25 probiotic types concluded that probiotic efficacy is both strain-specific and disease-specific.^[1] In that review, one Lactobacillus casei strain reduced antibiotic-associated diarrhoea to 6.7 percent while a different strain of the same species left it at 33.3 percent. Same species. Opposite result.

So this guide teaches the evaluation instead. By the end you should be able to pick up any bottle — one we have never heard of, one released next year — and work out in about ninety seconds whether there is real evidence behind it or only a large number on the front.

The short version, which the rest of this article defends: the headline numbers on a microbiome supplement label are weak predictors of whether the product has evidence behind it. The strain designation and the end-of-shelf-life potency statement are the two things that actually connect a product to published research.

What "microbiome supplement" actually covers

"Microbiome supplement" is a marketing bucket, not a scientific category. Four distinct product types sit inside it, and the International Scientific Association for Probiotics and Prebiotics (ISAPP) has published a consensus definition for each. Using them precisely is itself a filter, because product marketing routinely does not.

Two practical consequences follow immediately.

First, a large share of products sold under microbiome search terms contain no live organisms at all. Prebiotic fibre supplements and postbiotic preparations are legitimate categories with their own literature, but they are not probiotics and will not do what a probiotic does. Of the seventeen widely searched products whose labels we checked for this guide, three contained no live probiotic organisms.

Second, the umbrella phrase these products are sold under is itself contested. ISAPP convened a consensus panel in 2026 specifically to define "gut health," on the grounds that the phrase is used as a catch-all.^[6] If a label's central promise is "gut health" with nothing more specific attached, that is not a claim you can evaluate. It is a mood.

We cover the probiotic-versus-prebiotic distinction in more depth in our prebiotics versus probiotics guide.

The four criteria that qualify an organism as a probiotic

The cleanest evaluative checklist in the literature comes from a 2020 expert paper setting out what a microorganism must satisfy before it can honestly be called a probiotic.^[7] There are four criteria:

1. Sufficiently characterised. Identified to genus, species and subspecies by molecular methods, with whole genome sequencing described as the gold standard for strain identification. Proper designation means official nomenclature plus a strain identifier, and the strain should be deposited in a recognised culture collection so it remains available for research.
2. Safe for the intended use. Documented by history of use or by testing, including the absence of acquired antimicrobial resistance genes and known virulence factors.
3. Supported by at least one human clinical trial. At least one human trial demonstrating a health benefit is required to qualify a strain for probiotic status, preferably a double-blind randomised controlled trial.
4. Alive at an efficacious dose through shelf life. Viability at the efficacious dose should be documented in the products used in the clinical work, and guaranteed until the end of shelf life.

There is a useful corollary. Products that do not meet these criteria can still legitimately be labelled as containing "live, active cultures" — they simply should not be called probiotics. When you see that phrase instead of a strain-level probiotic claim, it is often an accurate description of what is in the bottle rather than a euphemism.

Reading the label, line by line

1. The strain line is the whole ballgame

A complete probiotic identity is genus, species, subspecies where one applies, and an alphanumeric strain designation. For example: Lacticaseibacillus rhamnosus GG, catalogue number ATCC 53103. The alphanumeric code is the part that lets you search the research literature and find out whether this organism has ever been trialled.

Three things routinely go wrong here.

Marketing nicknames are not strain designations. Trademarked names such as "Bifidus regularis" or "Bifantis" stand in for the actual identifier on some labels. You cannot look up a nickname in a research database. You can look up a designation.

The Lactobacillus genus was split in 2020. A taxonomic revision reclassified the old genus into 23 novel genera.^[8] Lactobacillus rhamnosus GG and Lacticaseibacillus rhamnosus GG are the same organism under two names, and older labels and older studies use the old one. This trips up shoppers constantly: a renamed strain looks like a different product. It is not.

A culture collection accession is more verifiable than a bare proprietary code. Identifiers that encode a recognised collection — ATCC, DSM, NCIMB, CECT, LMG, MTCC — point to a deposited, retrievable organism.

Is this filter actually predictive? A retail survey of refrigerated probiotic foods found that 49 percent, 22 of 45 distinct products, could be linked to evidence supporting any health benefit — and disclosure of the strain designation was the practical marker separating the two halves.^[9] A separate analysis documented a mismatch between the probiotic benefits demonstrated in trials and the strains and doses actually present in food products.^[10]

2. The CFU line: through expiration, not at manufacture

ISAPP's consumer guidance advises manufacturers to list the total number of colony-forming units, ideally per strain, through the expiration or use-by date, and advises consumers to avoid products that state CFU at time of manufacture, because a manufacture-time count does not account for decline over the product's life.^[11]

This is not a theoretical concern. Overfilling — adding excess viable cells at manufacture so the count stays above the label figure until the end of shelf life — is routine, and the surplus is not disclosed. One group of researchers puts the typical range at 1.5 to 4 times the labelled CFU, though they present that as an unpublished estimate drawn from their own work with European manufacturers rather than as a surveyed figure, and one of them is employed by a probiotic company.^[12] A genotyping survey of 52 US dietary supplements found 17 of them — a third — were below their labelled CFU claim before expiration.^[13]

"11 billion CFU at expiration" is a meaningfully stronger statement than "50 billion CFU." One is a guarantee about the product you will swallow. The other is a number about a moment in a factory.

3. Per-strain CFU in multi-strain products

If a label says "62 billion CFU" across fifteen organisms in a proprietary blend, you cannot tell whether the one strain with published trials is present at its trialled dose or is a trace ingredient. As ISAPP puts it in its consumer label guidance, you do not know whether equal amounts of all strains are included, or whether the bulk of the count is the strain that is cheapest to manufacture.^[11]

4. Storage conditions, and whether they were honoured

A stated storage condition is only worth something if the supply chain and your kitchen actually respected it. See the delivery section below — the honest answer here is more interesting than "refrigerated is better."

5. The prebiotic amount, in grams

In a synbiotic, check whether the prebiotic is listed in grams or milligrams. Bifidogenic doses in the trial literature generally sit between 1.5 and 30 grams per day. A capsule containing 50 milligrams of inulin is not delivering a prebiotic dose in the studied range. It is delivering a word on a label.

6. The structure/function disclaimer

Under US law a supplement may make a structure/function claim — the FDA's own examples include "calcium builds strong bones" and "fiber maintains bowel regularity" — but these claims are not pre-approved by the agency. The label must carry a disclaimer stating that the FDA has not evaluated the claim and that the product is not intended to diagnose, treat, cure or prevent any disease. The firm must notify the FDA of the claim's text no later than 30 days after it begins marketing with that claim. Only drugs may make disease claims. A supplement making an outright disease claim is being marketed unlawfully, and that tells you something about the company.

7. Third-party seals

USP Verified and NSF certification verify that what is on the label is in the bottle, and NSF also tests for contaminants. Neither verifies efficacy. And an important open question: we could not confirm, in either direction, whether the consumer-facing certification programmes verify probiotic identity at the strain level rather than the species level, or verify CFU through end of shelf life. Treat a seal as a contents check, not an evidence check.

What the label cannot tell you at all

• Whether the organism really is the strain claimed. That takes sequencing or PCR — which is exactly what the label-accuracy studies below do.
• Whether the cells are viable, viable-but-non-culturable, or dead. Plate-count CFU misses viable-but-non-culturable cells entirely, and flow cytometry shows that dead cells frequently represent a dominant fraction of a probiotic formulation.^[12]
• The overfill margin.
• Whether a coating actually protects the organism inside a living human.
• Whether the product will do anything for you specifically.

Does the CFU count predict benefit?

This deserves a straight answer, because it is the number most people shop on. The straight answer is: sometimes, for some endpoints, and there is no general rule that more is better.

The definitive review of probiotic dose-responses in human studies found the evidence splits cleanly in two.^[14]

Where a dose-response was observed:

• Antibiotic-associated diarrhoea. Meta-analyses suggest a dose-response effect, and dedicated dose-ranging studies show that faecal recovery and risk reduction follow a positive dose-response relationship. The review describes these findings as very compelling.
• Blood pressure, where a meta-analysis found doses above 10^11 CFU more effective than lower doses.
• Lactobacillus rhamnosus GG in acute paediatric gastroenteritis, where meta-analysis suggests a break-point for effectiveness.

Where no dose-response was found: Clostridioides difficile-associated diarrhoea, necrotising enterocolitis, prevention of atopic dermatitis, slow intestinal transit, colorectal cancer prophylaxis, irritable bowel syndrome, immune markers, general health and bowel function.

The review's own caveat matters as much as its findings: these results do not allow for extrapolation, and the absence of a clear dose-response for other endpoints does not prove one does not exist — the data simply do not allow a conclusion either way.

Then there is the single most awkward result for the "more is better" heuristic. In a trial of encapsulated Bifidobacterium longum 35624 in women with irritable bowel syndrome, the lowest dose tested, 1 x 10^8 CFU, was significantly superior to placebo and to all the higher bifidobacterium doses for abdominal pain and the composite symptom score.^[15] A hundred million CFU beat every larger dose in the same trial.

A note on that strain's name, because it is a live example of the lookup problem described above: the trial was published as Bifidobacterium infantis 35624, and the organism was later reclassified as B. longum subsp. longum 35624. The paper and the current label describe the same deposit under different names.

Add what CFU does not measure — the undisclosed overfill, the viable-but-non-culturable fraction, the dead cells, and the residual metabolites from the growth medium, all of which a plate count is blind to and some of which can still produce biological responses^[12] — and the conclusion is straightforward.

CFU is a potency and label-compliance unit, not an efficacy unit. The dose that matters is the dose used in the trial, for that strain, for that outcome. A higher CFU count on a different strain tells you nothing at all. Our CFU guide works through the arithmetic in more detail.

More strains is not more evidence

Strain counts have crept upward for the same reason CFU counts did: they are easy to print and easy to compare. The comparative literature does not support the assumption behind them.

Three reviews frame the question. An early analysis found only 16 studies that compared a mixture against its own component strains separately, with the mixture more effective in 12 of them — a result the authors hedged carefully as being based on a limited number of studies.^[16] A later review examined the market trend toward high-strain-count products and the assumptions behind it, namely that more strains hit more targets and that strains act additively or synergistically.^[17]

The most complete comparison is a systematic review of 65 randomised controlled trials — 41 single-strain, 22 multi-strain and 2 comparing a single strain against a mixture within the same trial — across eight disease indications and 10,863 participants.^[18] Its findings:

• Only three strains had trials with matching mixtures available for comparison at all, meaning a genuine head-to-head is almost never possible.
• One case where the single strain won: LGG alone was significantly more protective for necrotising enterocolitis than two mixtures containing different Bifidobacterium lactis strains.
• One case where the mixture won: LGG plus B. lactis Bb-12 was significantly more effective than LGG alone for Helicobacter pylori eradication.
• The overall conclusion, verbatim: in most cases single strains were equivalent to mixtures, and in most cases multi-strain mixtures were not significantly more effective than single-strain probiotics.

Where mixtures do appear to have an edge is in preterm infants, where guideline bodies point to combinations of Lactobacillus and Bifidobacterium species for prevention of necrotising enterocolitis and mortality^[19] — a finding that sits in direct tension with the single-strain result above. We flag the disagreement rather than pretending it resolves.

The decisive point for a shopper is not statistical, it is logical: combination effects cannot be extrapolated from evidence for the individual components. A 30-strain product is not thirty times the evidence. It is usually zero evidence for that particular blend. The question to ask a label is: has this combination been trialled, in humans, for anything?

Delivery, coatings, spores and the fridge

Survival without protection is genuinely poor

In a dynamic computer-controlled model of the stomach and small intestine, unformulated probiotic powder showed 5.3 percent survival for bifidobacteria and 1 percent for Lactobacillus gasseri through the gastric compartment; an optimised enteric-coated tablet substantially increased delivery of viable cells to the small intestine.^[20] That is the cleanest published number for why formulation matters.

But here is the honest caveat

We found no evidence that enteric coating improves clinical outcomes in humans. The coating literature reviewed for this guide is in vitro survival work and formulation science. Efficacious doses were established in trials that used whatever formulation those trials used — for many landmark strains, an ordinary capsule or a food matrix. The B. longum 35624 trial that beat higher doses used an encapsulated product at 100 million CFU.^[15] Delivery format and dose interact in ways a label cannot resolve for you.

A coating claim is a plausible engineering advantage. It is not clinical evidence, and it should not be paid for as though it were.

Spore-formers

Spore-forming organisms — Bacillus coagulans, Bacillus subtilis, Bacillus clausii — produce endospores that survive gastric acid and processing better than vegetative cells. Two human studies support the survival claim specifically. In a randomised crossover study in healthy volunteers, B. clausii was found alive in faeces for up to 12 days, with evidence of germination, outgrowth and multiplication as vegetative forms.^[21] In an ileostomy study sampling small-intestinal effluent directly — 11 participants, small but methodologically strong — B. subtilis DE111 was present and germinating.^[22]

Stability data are the strongest argument for spores. A 12-month storage study across three temperatures compared vegetative Lactobacillus acidophilus LA-1 with three Bacillus spore strains in cookies and crackers.^[23]

Note what that table also shows: "spore-based" is a category claim, not a potency guarantee. The three Bacillus strains differed from each other by more than two logs.

Two caveats cut against spores. First, stability is not efficacy — nothing we reviewed shows spore-formers outperforming vegetative strains on clinical endpoints. Second, a shotgun metagenomics survey of 50 US supplements found antimicrobial resistance genes in several products, with Bacillus-based products carrying between 10 and 56 such genes.^[24] Absence of acquired resistance genes is one of the four qualifying criteria for a probiotic.^[7]

Refrigerated versus shelf-stable

Vegetative cells lose viability with heat, humidity and time, and water activity drives this as much as temperature does. But for well-selected spore strains, refrigeration conferred no significant benefit in the 12-month study above.^[23]

The defensible position: "refrigerated" is not inherently better than "shelf-stable." It depends on the organism and the formulation. What matters is whether the manufacturer guarantees the labelled count at the end of shelf life under the stated storage conditions. A "refrigeration required" product that sat on a warm loading dock is worse than a properly validated shelf-stable one.

Matching a strain to a goal

This is where a strain designation earns its keep. Below is what the literature reviewed for this guide has actually examined — not what any product promises. Several of these findings concern survival or dosing rather than clinical benefit, and the table says which.

Notice how short that list is compared with the promises on a supplement shelf. That is the point. For most outcomes people shop for — energy, bloating relief, weight, mood, "detox" — the strain-level evidence is absent, thin or contested, and the honest response is to say so.

Our strain profiles go deeper on individual organisms: Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus acidophilus, Bifidobacterium breve, B. longum subsp. infantis, Saccharomyces boulardii and Akkermansia muciniphila. The strain comparison chart puts them side by side.

Prebiotic fibres, as an alternative or a complement

A prebiotic is a substrate selectively used by host microorganisms to confer a health benefit.^[3] It feeds what you already have rather than adding organisms. For many people that is the more sensible starting point, and it is cheaper.

The critical number is dose. In a dose-dependent study of high-purity galacto-oligosaccharides in healthy adults, 5 grams or more was bifidogenic while 2.5 grams showed no effect.^[28] In a 200-volunteer study, the screening phase compared seven non-digestible carbohydrates at 10 grams per day and found four of them bifidogenic: short-chain fructo-oligosaccharides, soybean oligosaccharides, galacto-oligosaccharides and type III resistant starch. Lactulose, long-chain inulin and isomalto-oligosaccharides were not.^[29] Across the literature, effective prebiotic doses generally sit in the 1.5 to 30 grams per day range.

Hold that range next to a synbiotic capsule listing 50 milligrams of inulin and the mismatch is obvious. It is one of the few things on a label you can check with arithmetic alone.

Fibre-by-fibre detail lives on our individual pages: galacto-oligosaccharides, fructo-oligosaccharides, inulin, xylo-oligosaccharides, resistant starch, psyllium husk, beta-glucan, acacia fibre, pectin, arabinoxylan, lactulose and human milk oligosaccharides. For a food-first approach, see our prebiotic foods guide and gut-healthy diet guide.

One caution: fermentable fibres produce gas by design. If bloating is your presenting complaint, escalate the dose slowly rather than starting at the top of the studied range.

Synbiotics and postbiotics: read these definitions carefully

Synbiotics

The consensus statement defines two subtypes.^[4] A complementary synbiotic is one in which the probiotic and prebiotic act independently; each component must independently meet the probiotic and prebiotic criteria at effective doses, and the combination must be shown in an appropriately designed trial to confer a health benefit. A synergistic synbiotic is one in which the substrate is designed to be selectively used by the co-administered microorganisms; components need not individually qualify, but evidence must demonstrate selective utilisation and a health benefit in the same study, showing the combined effect is better than the estimated effects of each component separately.

The commercially decisive sentence is this one: a product containing a probiotic and a prebiotic that only has evidence for each component individually should not be called a synbiotic. The panel also notes that nearly all synbiotics used in published trials or sold commercially are of the complementary form.

Nor is synergy something to assume. A study in obese adults found that Bifidobacterium strains and galacto-oligosaccharides each improved intestinal barrier function — and showed no synergism when used together.^[30] Formulating synbiotics rationally remains an open design problem.^[31]

Postbiotics

A postbiotic is a preparation of inanimate microorganisms and/or their components that confers a health benefit.^[5] The consensus statement sets six requirements, including molecular characterisation of the parent organisms, a detailed description of the inactivation procedure, confirmation that inactivation occurred, evidence of benefit from a controlled high-quality trial, a full composition description, and a safety assessment in the target host.

Just as important is what the definition excludes: purified metabolites on their own such as butyric or lactic acid, vaccines, substantially purified components, filtrates without cell components, chemically synthesised compounds, bacteriophages, and products from undefined microorganisms. That exclusion list disqualifies a good deal of what is sold as a postbiotic in the US market, where the definition is not enforced. If you are buying isolated butyrate or a cell-free filtrate, it may still be worth buying — but it is not a postbiotic by the consensus definition.

The best single postbiotic trial retrieved for this guide tested heat-inactivated B. bifidum MIMBb75 in IBS: 34 percent of the treatment group reached the composite endpoint versus 19 percent on placebo, a relative risk of 1.7.^[26] Read alongside it the published correspondence responding to that trial, titled "Paraprobiotics for irritable bowel syndrome: all that glitters is not gold."^[27] We flag its existence rather than summarising it, because we have not read it in full — but a single positive trial with a live methodological debate attached is not a settled result.

ISAPP's own assessment of the postbiotic evidence base is that it is limited and variable in quality, with only limited evidence in children, and safety and potential harms poorly explored. The genuine advantages of postbiotics are stability and a plausibly better safety profile in fragile populations, not a deeper evidence base.

What the label-accuracy studies actually found

This is where consumer coverage tends to pick a side. The honest presentation shows the spread.

Modern US-market surveys using DNA-based methods cluster somewhere between 8 and 33 percent inaccuracy. That is dramatically better than the worst historical findings and dramatically worse than most shoppers assume. One caveat on the most favourable of these: we did not retrieve its funding and conflict-of-interest statement, and its authors sit in a natural-health-products research group with industry relationships, so we present it as one point in a range rather than as a rebuttal.

The single most consistent failure mode is subspecies-level error — B. longum subsp. longum sold as subsp. infantis — which recurs across independent studies a decade apart.^[32][33] That matters because those two subspecies have different metabolic capacities, and because subspecies-level identification is one of the qualifying criteria for a probiotic.^[7]

Two more practical notes. Expired products are not automatically empty: a survey of products a mean of 11.3 years past expiration found 22 still had viable contents.^[35] That is a curiosity, not a licence — buy well inside the date. And the professional societies agree this is systemic: a paediatric working group published a position paper calling for improved quality control in commercial probiotic products.^[36]

The regulatory backdrop, in one paragraph

The FDA does not approve dietary supplements before they are marketed, does not review their labelling in advance, and does not test them before sale. Under the 1994 dietary supplement statute, manufacturers are responsible for evaluating the safety and labelling of their own products and for following current good manufacturing practices; the agency's role is post-market enforcement against adulterated or misbranded products, prioritised toward public health emergencies and products that may have caused injury or illness. Standards-setting is voluntary. USP publishes monographs covering identification, enumeration and contaminant limits for supplements, and the same body notes there is no global harmonisation regarding requirements for establishing probiotic safety for use in foods and supplements.^[37] In short: nobody checked this bottle before it reached the shelf. You are the quality control step.

What the research does not support

It is worth stating plainly what a guide like this cannot tell you to buy.

• That a higher CFU count is better. No general dose-response exists across endpoints, and at least one trial found the lowest dose best.^[14][15]
• That more strains are better. In most cases single strains were equivalent to mixtures.^[18]
• That an enteric coating improves outcomes. No human clinical-outcome evidence was found; the case rests on in vitro survival.^[20]
• That spore-formers work better. Their documented advantage is stability and gastric survival, not clinical superiority.^[23][22]
• That a probiotic plus a prebiotic in one capsule is synergistic. Assume complementary at best; one well-designed test found no synergism.^[30]
• That probiotics as a category do what most people buy them for. Clinical guidance suggests probiotics for prevention of C. difficile infection in adults and children taking antibiotics, for prevention of necrotising enterocolitis and mortality in preterm low-birth-weight infants, and for pouchitis — while finding the evidence insufficient for Crohn's disease, ulcerative colitis, IBS and treatment of C. difficile infection, and recommending against routine use for acute gastroenteritis in children.^[19]

That last point deserves an extra beat, because guideline bodies do not agree with each other, and the disagreement is itself informative. A 2026 review notes that at least six professional societies have published probiotic guidelines for gastrointestinal disorders and that no two align perfectly, and it attributes the divergence to how panels pool or separate strains, to the subjective elements of grading imprecision and clinical meaningfulness when effect sizes are small, and to differences in search timeframes and inclusion criteria.^[25] On the pooling problem it cites one guideline's technical review, which found 76 published trials in irritable bowel syndrome testing 44 different strains or combinations between them — with a single trial constituting the whole evidence base for most of the products that reported a benefit. Its worked example compares two guidelines directly: one recommends against probiotics for acute gastroenteritis in children, while the other recommends four specific treatments for it, issues a conditional recommendation against B. clausii strains, and strongly recommends two probiotics for antibiotic-associated diarrhoea prevention.

The conclusion is not "probiotics don't work." It is that the question "do probiotics work?" is malformed. Specific strains, at specific doses, have specific evidence for specific outcomes, and for most of what shoppers care about that evidence is absent, thin or contested.

Safety: who should not self-prescribe

Probiotics are widely tolerated by healthy people. The literature also documents real risks in defined populations, and a buyer's guide that omits them is incomplete.

The strongest single piece of evidence: among ICU patients receiving LGG, 6 of 522 (1.1 percent) developed Lactobacillus bacteraemia, versus 2 of 21,652 (0.009 percent) among those not receiving it.^[38] Whole-genome sequencing found the blood isolates aligned most closely to the LGG reference genome and were phylogenetically inseparable from the capsule isolates, with five de novo mutations appearing only in blood isolates — including one conferring rifampin resistance. The authors' framing is the right one: potential benefits must be weighed against this risk in patients whose risk is elevated.

The populations where the literature counsels caution: critically ill and ICU patients, immunocompromised people, patients with central venous catheters, patients with severe active inflammatory bowel disease on immunosuppression, neutropenic patients, post-surgical patients, and premature or low-birth-weight infants — the last being a genuine risk-benefit tension, since that is also where the benefit evidence is strongest. Add to this the antimicrobial resistance gene findings in commercial products.^[24]

If you are in any of these groups, this is a conversation with a clinician, not a purchase decision.

What commonly searched brands do and do not disclose

The products below are the ones people actually search for under microbiome supplement terms. We did not test any of them. What follows is only what each manufacturer publishes, checked against the NIH Dietary Supplement Label Database where a printed Supplement Facts panel is archived there, as of 9 September 2026. Formulations and prices change; inclusion here is not a recommendation, and exclusion is not a criticism.

We are reporting on one axis only — the axis this whole guide argues matters: can you tell what is in it, and has the finished product been tested in humans?

Six observations are worth more than the table.

Only three cite a published human trial on the actual finished formula — and all three are manufacturer-authored or manufacturer-connected. Seed publishes three RCTs on the complete DS-01 formulation: one with 350 participants over six weeks on bloating, gas and abdominal discomfort in a generally healthy population recruited for self-reported bloating^[39]; one with 32 participants over 91 days on microbial diversity, urolithin A, butyrate and C-reactive protein^[40]; and one over 91 days on microbiome recovery and gut barrier integrity during and after a course of antibiotics.^[41] Seed Health employees and shareholders are among the authors of all three, and Seed sponsored them, though the trials were run by contract research organisations. BiotiQuest publishes one RCT on Sugar Shift; the brand is wholly owned by a company part-owned by an author who took part in designing the study, and the trial used an 18 billion CFU version while the current product page lists 22 billion.^[42] Pendulum publishes one RCT of its five-strain formulation in type 2 diabetes, authored entirely by company employees and shareholders, in which the primary endpoint p-value sits exactly at the conventional significance threshold at p=0.0500.^[43] None of that makes these trials worthless — a manufacturer-funded RCT on the finished product is a great deal more than most of the category offers, and the outcomes studied were digestive-symptom and biomarker endpoints, not disease treatment. It does mean the funding belongs in the same sentence as the result. Pendulum's glucose product has additionally been reported as being marketed as a medical food; we could not confirm that designation on the manufacturer's own product page, and in any case "medical food" is a regulatory category, not an FDA finding of efficacy.

"Clinically studied strains" is not the same claim as "clinically studied product." Ritual's Synbiotic+ names two of the most-studied organisms in the literature, LGG and BB-12, and its label states 11 billion CFU at expiration rather than at manufacture, which is the more informative of the two industry conventions. But the trials belong to those strains as ingredients, not to the finished product, and a well-disclosed label is a disclosure claim rather than an efficacy claim. That distinction is the one most shoppers do not notice, and it applies to every product on this list that names a studied strain.

Three of these contain no live probiotic organisms at all. BiotaGen and ImproBiome are prebiotic fibre products — BiotaGen's powder lists a 5 gram blend of chicory inulin, yeast-derived beta-glucan and larch arabinogalactan, which is a real prebiotic dose, though its capsule form delivers less; ImproBiome lists 1,957 mg of total prebiotic fibre per serving, below the studied range discussed above. Astrobiome is marketed as a postbiotic. Anyone arriving from a probiotic search is miscategorising all three.

Two labels do not support the CFU figure repeated at retail. Purium's Biome Medic panel lists LactoSpore at 15 mg per capsule and states no CFU count at all, while reseller listings circulate billions-of-CFU figures for it. Fifteen milligrams is a small enough quantity that no double-digit-billion per-capsule count is arithmetically available from any commercially standardised Bacillus coagulans ingredient, but the correct response to a missing number is to treat it as missing rather than to substitute a calculated one. Eidon's SuperBiome likewise does not publish a CFU count. If you cannot find the per-serving number on the manufacturer's own panel, you cannot compare the product to anything.

Price does not track evidence. Astrobiome is priced at roughly $235 to $245 for a month's supply, publishes no Supplement Facts panel, no source organism, no quantified metabolite, and cites no study, registry number or publication anywhere we could retrieve — while listing an unusually broad span of outcome claims. Eidon's SuperBiome, at a small fraction of that, discloses species only. Pendulum's Glucose Control sits at the expensive end of the list and is one of only three products here with an own-formula trial, while several of the cheaper products disclose more about what is in them than several of the dearer ones. Prices move constantly and we have not tracked them systematically; the point is only that cost is not a proxy for evidence in either direction.

Two brand names collide with themselves. "Superbiome" returns at least two unrelated products: a mushroom-and-probiotic capsule from Eidon and a probiotic-plus-prebiotic system from Juice Plus+. "3Biome" is sold by Nutreance as a transparent three-strain Bacillus product, while listings under the same name advertise ten-strain and 50-billion-CFU configurations we could not verify as coming from the same company. And Bioma sells its flagship as a branded proprietary blend of Bifidobacterium species with no strain designations printed, is not listed in the NIH label database, and has more than one formula description in circulation under the same brand. If you cannot pin down which SKU you are buying, the strain designation question cannot even be asked.

For a broader look at strain-by-condition evidence, see our guides to the best probiotics by strain and condition, probiotics for IBS and how long probiotics take to work.

A ninety-second checklist for any bottle

1. Find the full strain designation. Genus, species, subspecies where applicable, and an alphanumeric code. No code, no lookup, no evidence trail.
2. Check whether CFU is guaranteed at expiration or only at manufacture. Prefer the former, every time.
3. In a multi-strain product, look for per-strain CFU. Without it, you cannot tell whether the studied strain is the bulk of the dose or a rounding error.
4. Ask whether the combination was trialled, not just the components.
5. Read the prebiotic in grams. Milligram quantities of inulin are decorative.
6. Check the storage statement — and be honest about whether your supply chain honoured it.
7. Check the date, and buy well inside it.
8. Look for the structure/function disclaimer. Its presence is normal. An outright disease claim is a red flag about the company, not a sign of a stronger product.
9. Treat a third-party seal as a contents check, not an efficacy check.
10. Search the strain code, not the brand name. If the designation returns nothing in the literature, you have your answer.

Bottom line

There is no best microbiome supplement, and the products that market themselves hardest on the two numbers shoppers compare — CFU and strain count — are competing on the two variables with the weakest link to published evidence. The strain designation and the end-of-shelf-life potency statement are the two label elements that connect a bottle to research, and they are both free to print. Their absence is a choice.

If you want a rational starting point rather than a purchase: get the fibre dose right first, since the effective range is well characterised and the intervention is cheap; if you do buy a probiotic, buy a fully designated strain at the dose used in the trial for the outcome you care about; and if you are in one of the clinical groups where bacteraemia has been documented, ask a clinician before you buy anything at all. If you want to know what is in your gut before spending money on changing it, start with our microbiome testing guide.

This article is for educational purposes and is not medical advice. Product information reflects manufacturer disclosures and label records retrieved on 9 September 2026 and may since have changed; no product mentioned is endorsed, and none is intended to diagnose, treat, cure or prevent any disease. Talk to a healthcare provider before starting a supplement, particularly if you are pregnant, immunocompromised, critically ill, or taking medication.